Y-mAbs Q4 2023 Earnings Report
Key Takeaways
Y-mAbs reported a net loss of $1.0 million for Q4 2023, with DANYELZA net product revenues reaching $23.4 million, a 42% increase compared to the same period in 2022. The company's cash and cash equivalents were approximately $78.6 million as of December 31, 2023, expected to support operations into 2027.
DANYELZA net product revenues were $23.4 million, a 42% increase year-over-year.
Research and development expenses decreased by 32% compared to the same quarter in the previous year.
Net loss for the quarter was $1.0 million, compared to net income of $1.2 million in Q4 2022, which included $15.0 million of license revenue.
Cash and cash equivalents totaled $78.6 million as of December 31, 2023.
Y-mAbs
Y-mAbs
Forward Guidance
Y-mAbs expects its cash and cash equivalents, together with anticipated DANYELZA product revenues, to support operations as currently planned into 2027.